Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disney

Devon Energy

Ecolab

Ford Motor Company

Lennar

Live Nation

Netflix

Under Armour

The three major U.S. equities indexes closed lower again on Thursday for the third day in a row.

5 S&P 500 Winners, 5 Losers in Friday's Premarket

Following the trade, the Charitable Trust will own 475 shares of Eli Lilly.

We're putting cash to work by buying more shares of this drugmaker

INDIANAPOLIS, Jan. 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement

AbbVie

Catalyst Pharmaceuticals

Horizon Pharma

Innoviva

Pfizer

Zoetis

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.

7 of the Top-Rated Pharmaceutical Stocks for Q1

Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly And Co (NYSE: LLY) for novel molecules against an undisclosed target for cardiometabolic diseases. Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform.

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

GlaxoSmithKline

An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc (NYSE: GSK) / Vir Biotechnology Inc (NASDAQ: VIR) for COVID-19 patients. In its guidelines published in the British  Medical Journal , the panel has recommended Lilly's baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, combined with corticosteroids for severe COVID-19 patients.

WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge

We question the magnitude of Eli Lilly's decline for a few reasons.

We think the selling in Eli Lilly may be overblown

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Eli Lilly (LLY) Recently Broke Out Above the 50-Day Moving Average

Church & Dwight

Dover

Fortinet

Iron Mountain

Kroger

Signature Bank

J. M. Smucker

Wells Fargo

Here're seven of the best performing stocks that saw record gains in the past 12 months The post The 10 Best Performing Stocks in the S&P 500 for 2021 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

The 10 Best Performing Stocks in the S&P 500 for 2021

Eli Lilly and Company (LLY) Presents at 40th Annual JP Morgan Healthcare Conference (Transcript)

Eli Lilly (LLY) closed the most recent trading day at $262.32, moving +0.85% from the previous trading session.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

AstraZeneca

Bristol-Myers

Merck

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

3 Big FDA Approvals to Watch For in Q1 2022

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications

Amgen

Gilead Sciences

Novocure

United Therapeutics

SPDR S&P Pharmaceuticals ETF

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 Pharmaceutical Stocks That Could Make You Rich

INDIANAPOLIS and EDMONTON, AB, Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system, the companies announced today. This technology provides an opportunity for Lilly to access a novel delivery platform technology with the potential to solve a key delivery challenge for many nucleic acid therapeutic modalities.

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Bausch Health Companies Inc

Chevron

Honeywell

Appearing on CNBC's "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.

Here are 4 of Jim Cramer's top stock picks for 2022

Strong pipeline with multiple potential blockbuster drugs should fuel revenue growth in the foreseeable future. The highly visible nature of potential Alzheimer's treatment donanemab is likely to overshadow the other new, lower risk treatments in the pipeline.

Eli Lilly: Expecting Market Performance

Acadia Healthcare

Jazz Pharmaceuticals

Health care stocks to watch as coronavirus cases show no signs of slowing down.

Top Stocks To Invest In 2022? 4 Health Care Stocks To Check Out

Eli Lilly (LLY) closed the most recent trading day at $271.73, moving -1.63% from the previous trading session.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Several drug companies announced their annual dividend increases in December. Eli Lilly surprised to the upside with a 15% boost, while Pfizer increased its dividend by only 2.5%. The big surprise in December was Nucor which, after several years of slow dividend growth, boosted its payout by 23%.

Eli Lilly Leads The Way As Drug Companies, Others Boost Dividends In December

Their momentum could continue into the new year.

3 Dividend Stocks That Soared More Than 50% in 2021 and Are Still Great Buys

Regeneron Pharmaceuticals

Regulators say it is "unlikely" the drugs will have an effect against the new variant, pending new data.

U.S. Halts Distribution of Regeneron and Eli Lilly Covid Antibody Drugs

Adobe

Costco

Investors have seen great returns from these companies in recent years -- and the future looks bright too.

3 Unstoppable Stocks to Buy for 2022

We think Eli Lilly's recent pullback from recent highs gives investors a second chance to start or further add to positions.

Cramer's Investing Club: Recent drop in a portfolio drug stock only a minor setback

Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

News for Eli Lilly Stock (LLY)